Alkermes NewsOvjeren akaunt

@Alkermes

Official Twitter feed of Alkermes. We develop new medicines designed to improve the health of people living with serious chronic central nervous system diseases

Vrijeme pridruživanja: ožujak 2017.

Tweetovi

Blokirali ste korisnika/cu @Alkermes

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Alkermes

  1. 28. sij

    The has accepted for review our NDA for ALKS 3831, seeking approval for the treatment of & . This is an encouraging step in our pursuit to deliver new medicines to treat serious disorders:

    Poništi
  2. 15. sij

    “Alkermes R&D capabilities are strong and have evolved significantly over the past several years… The ecosystem is increasingly demanding new medicines based on new biology, and we have been working in that direction for the past several years.”

    Poništi
  3. 15. sij

    Join us tomorrow at as CEO Richard Pops takes the stage to share updates on the company’s work to develop innovative medicines for .

    Poništi
  4. 13. sij

    Join us live at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 9:00 a.m. PT (12:00 p.m. ET) to see our CEO Richard Pops as he discusses how we are shaping the future of Alkermes

    Poništi
  5. Proud to announce that our own distinctive HR leader, Madeline Coffin, has receive the Award of Distinction from . Congratulations to Madeline and all the award recipients!

    Poništi
  6. We are heading to London in just a week and are looking forward to attending the ! Read more about the award ceremony and finalists here:

    Poništi
  7. November is Lung Cancer Awareness Month. Lung cancer is the second most common cancer and the leading cause of cancer death, taking about 156,000 American lives each year. Recognize the risk factors

    Poništi
  8. Mark Namchuk, svp, research, pharmaceutical, and non-clinical development discussing his insights on R&D culture and its impact on at today’s

    Poništi
  9. We are proud to share that the ALKS 3831 ENLIGHTEN-2 study for schizophrenia was recognized with a “highly commended” accolade for the 2019 Clinical Trial of the Year at the . Thank you for this honor

    Poništi
  10. Congratulations to our excellent HR Leader, Madeline Coffin, for her nomination for an 2019 HR Excellence Award! Best of luck to all of the nominees!

    Poništi
  11. Today we announced the submission of a New Drug Application to the seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder. View our press release to learn more:

    Poništi
  12. proslijedio/la je Tweet
    18. stu 2019.

    Congratulations to and on advancing important research for neurological diseases -- "Alkermes to Acquire Rodin Therapeutics"

    Poništi
  13. proslijedio/la je Tweet
    18. stu 2019.

    Very proud of what our team ⁦⁩ has accomplished over 4+ years of cutting-edge research in challenging neurological areas with massive unmet need - look forward to continued progress ⁦

    Poništi
  14. Alkermes is excited to announce our pending acquisition of to build on our experience in central nervous system (CNS) diseases and expand our CNS development efforts into a wide range of neurodegenerative disorders. More information:

    Poništi
  15. This week, and always, we salute nurse practitioners and the essential role they play in care.

    Poništi
  16. Today, we honor Chris, colleague & Marines , whose dedication to ppl living with extends beyond his job & into the community he's deeply connected to. We thank him, & all active duty military & veterans, for their service. Watch his story:

    Poništi
  17. Thank you to all who joined us at . We are energized more than ever to advance research in oncology.

    Poništi
  18. Thanks to everyone who attended our presentation at . If you missed it, stop by Alkermes Booth 203 to learn about a treatment for adults with .

    Poništi
  19. Right now, Stephen R. Saklad, PharmD, BCPP, is talking about the importance of the . Come to this live presentation at The Broadmoor, Colorado Hall and learn about a treatment for adults.

    Poništi
  20. Join the Alkermes product theater at . Learn about a for . Discussing treatment options supports the with patients and care teams. Can’t make it? Visit Alkermes Booth 203 to learn more.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·